Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation
- PMID: 25213406
- DOI: 10.1016/j.virol.2014.08.008
Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation
Abstract
The highly conserved internal nucleoprotein (NP) is a promising antigen to develop a universal influenza A virus vaccine. In this study, mice were injected intramuscularly with Escherichia coli-derived NP protein alone or in combination with adjuvant alum (Al(OH)3), CpG or both. The results showed that the NP protein formulated with adjuvant was effective in inducing a protective immune response. Additionally, the adjuvant efficacy of Al(OH)3 was stronger than that of CpG. Optimal immune responses were observed in BALB/c mice immunized with a combination of NP protein plus Al(OH)3 and CpG. These mice also showed maximal resistance following challenge with influenza A virus PR8 strain. Most importantly, 10 µg NP formulated with Al(OH)3 and CpG induced higher protection than did 90 µg NP. These findings indicated that a combination of Al(OH)3 and CpG may be an efficient adjuvant in the NP formulation.
Keywords: Al(OH)(3); CpG; Influenza A virus; Nucleoprotein; Protective immunity; Protein subunit vaccines.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.Microb Cell Fact. 2015 Aug 5;14:111. doi: 10.1186/s12934-015-0287-4. Microb Cell Fact. 2015. PMID: 26242406 Free PMC article.
-
Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.Hum Vaccin Immunother. 2015;11(2):397-406. doi: 10.4161/21645515.2014.995056. Hum Vaccin Immunother. 2015. PMID: 25607884 Free PMC article.
-
Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.PLoS One. 2012;7(12):e52488. doi: 10.1371/journal.pone.0052488. Epub 2012 Dec 21. PLoS One. 2012. PMID: 23285063 Free PMC article.
-
IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.Arch Virol. 2018 Apr;163(4):877-886. doi: 10.1007/s00705-017-3682-9. Epub 2017 Dec 21. Arch Virol. 2018. PMID: 29270718
-
Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.J Immunol. 1999 Apr 1;162(7):4163-70. J Immunol. 1999. PMID: 10201942
Cited by
-
Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.Plant Cell Rep. 2015 Jun;34(6):969-80. doi: 10.1007/s00299-015-1758-0. Epub 2015 Feb 13. Plant Cell Rep. 2015. PMID: 25677970
-
Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.Sci Rep. 2022 Jul 16;12(1):12189. doi: 10.1038/s41598-022-16365-2. Sci Rep. 2022. PMID: 35842468 Free PMC article.
-
Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Clin Vaccine Immunol. 2015 Jun;22(6):618-30. doi: 10.1128/CVI.00091-15. Epub 2015 Apr 1. Clin Vaccine Immunol. 2015. PMID: 25834017 Free PMC article.
-
Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.J Microbiol Biotechnol. 2021 Feb 28;31(2):304-316. doi: 10.4014/jmb.2011.11029. J Microbiol Biotechnol. 2021. PMID: 33263336 Free PMC article.
-
Selecting and Using the Appropriate Influenza Vaccine for Each Individual.Viruses. 2021 May 24;13(6):971. doi: 10.3390/v13060971. Viruses. 2021. PMID: 34073843 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous